Comparative Pharmacology
Head-to-head clinical analysis: CODEINE SULFATE versus QDOLO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CODEINE SULFATE versus QDOLO.
CODEINE SULFATE vs QDOLO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Codeine sulfate is a prodrug that is metabolized to morphine, which acts as a mu-opioid receptor agonist, producing analgesia by mimicking the action of endogenous opioids. It also binds to kappa and delta opioid receptors, leading to reduced neurotransmitter release and altered pain perception.
Tramadol is a centrally acting synthetic opioid analgesic. It binds to μ-opioid receptors and inhibits norepinephrine and serotonin reuptake.
15-60 mg orally every 4-6 hours as needed for pain; maximum 360 mg per day.
Oral: 50-100 mg every 4-6 hours as needed for pain; maximum 400 mg per day. Immediate-release tablets only. Extended-release formulations require different dosing and are not interchangeable.
None Documented
None Documented
2.5-3.5 hours (terminal) in adults; prolonged in hepatic impairment (up to 5-6 hours) and elderly
Terminal elimination half-life approximately 2-4 hours in adults; prolonged to 4-6 hours in elderly and up to 12-16 hours in severe renal impairment (CrCl <30 mL/min)
Renal: 90% (as morphine, norcodeine, and codeine conjugates); Fecal: <10%; Biliary: minimal
Renal 90% (60% unchanged, 30% as glucuronide conjugate), fecal 10%
Category D/X
Category C
Opioid Agonist
Opioid Agonist